- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT03560752
기증자 줄기 세포 이식을 받는 혈액암 참가자의 CMV 바이러스혈증 예방을 위한 줄기 세포 기증자의 CMV-MVA 삼중 백신 접종
줄기 세포 이식 후 수혜자의 CMV 특이 면역을 강화하고 CMV 바이러스혈증을 예방하기 위한 줄기 세포 기증자의 CMV-MVA 삼중 백신 접종
This phase II trial studies how well multi-peptide CMV-modified vaccinia Ankara (CMV-MVA Triplex) vaccination of stem cell donors works in preventing cytomegalovirus (CMV) viremia in participants with blood cancer undergoing donor stem cell transplant. Giving a vaccine to the donors may boost the recipient's immunity to this virus and reduce the chance of CMV disease after transplant.
연구 개요
상태
정황
상세 설명
PRIMARY OBJECTIVES:
I. Establish the feasibility and safety of priming CMV immunity in donors by Triplex vaccination prior to peripheral blood stem cell (PBSC) harvest.
SECONDARY OBJECTIVES:
I. Examine if Triplex vaccination of hematopoietic stem cell transplant (HCT) donors has an impact on CMV events.
OUTLINE:
Donors receive multi-peptide CMV-modified vaccinia Ankara vaccine injection between days -60 and -10 prior to granulocyte colony stimulating factor mobilization. Participants undergo hematopoietic cell transplantation on day 0.
After completion of study treatment, participants are followed up for 1 year.
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
California
-
Duarte, California, 미국, 91010
- City of Hope Medical Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- DONOR: Ability to comprehend the investigational nature of the study and provide informed consent
- DONOR: Willing to receive Triplex vaccination, a minimum of 14 days prior to the PBSC collection
- DONOR VACCINATION: Donors are eligible to be vaccinated prior to the determination of their human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and human T-cell lymphotropic virus (HTLV) status. The exclusion criteria for transplant is independent of eligibility for vaccination and is determined by the exclusion criteria for transplant from donors
- RECIPIENT: All subjects must have the ability to understand and the willingness to sign a written informed consent
- RECIPIENT: Participant must be willing to comply with study and/or follow-up procedures, including willingness to be followed for one year post-HCT
- RECIPIENT: Age 18 to 75 years
- RECIPIENT: Planned HCT for the treatment of the following hematologic malignancies: lymphoma (Hodgkin and non-Hodgkin), myelodysplastic syndrome, acute lymphoblastic leukemia in first or second remission, acute myeloid leukemia in first or second remission, chronic myelogenous leukemia (in first chronic or accelerated phase, or in second chronic phase), chronic lymphocytic leukemia, myeloproliferative disorders and myelofibrosis (City of Hope [COH] only). Patients with multiple myeloma are excluded
- RECIPIENT: CMV seropositive
- RECIPIENT: Planned related HCT with 8/8 (A, B, C, DRB1) high resolution HLA donor allele matching
- RECIPIENT: Conditioning and immunosuppressive regimens according to institutional guidelines are permitted
- RECIPIENT: Negative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration
- RECIPIENT: Seronegative for HIV, HCV and active HBV (surface antigen negative) within 2 months of registration
- RECIPIENT: Agreement by females of childbearing potential and males with partners of childbearing potential to use effective contraception (hormonal or barrier method or abstinence) prior to study entry and for up to 90 days post-HCT. Should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
Exclusion Criteria:
- TRANSPLANT FROM DONOR: Unfit to undergo standard stem cell mobilization and apheresis e.g. abnormal blood counts, history of stroke, uncontrolled hypertension
- TRANSPLANT FROM DONOR: Sickling hemoglobinopathy including HbSS, HbAS, HbSC
- TRANSPLANT FROM DONOR: Positive for human immunodeficiency virus (HIV), active hepatitis B (hepatitis B virus [HBV]), hepatitis C (hepatitis C virus [HCV]) or human T-cell lymphotropic virus (HTLV-I/II). This holds true even if donors have been already vaccinated according to criteria for donor vaccination
- TRANSPLANT FROM DONOR: Donors with impaired cardiac function are excluded. Electrocardiography is routine for potential HCT donors over 60 years old and those with a history of heart disease. Subjects in whom cardiac function is abnormal (excluding 1st degree branch block, sinus brachycardia, sinus tachycardia or non-specific T wave changes) are ineligible for Triplex vaccination
- TRANSPLANT FROM DONOR: Severe psychiatric illness. Mental deficiency sufficiently severe as to make compliance with the donation procedure unlikely, and making informed consent impossible
- RECIPIENT: Any prior investigational CMV vaccine
- RECIPIENT: Experimental anti-CMV chemotherapy in the last 6 months
- RECIPIENT: Planned medications from the time of HCT to day 70 post-HCT
- RECIPIENT: Live attenuated vaccines
- RECIPIENT: Medically indicated subunit (Engerix-B for HBV; Gardasil for human papillomavirus [HPV]) or killed vaccines (e.g. influenza, pneumococcal, or allergy treatment with antigen injections)
- RECIPIENT: Allergy treatment with antigens injections
- RECIPIENT: Alemtuzumab or any equivalent in vivo T-cell depleting agent
- RECIPIENT: Antiviral medications with known therapeutic effects on CMV such as ganciclovir (GCV)/valganciclovir (VAL), FOS, Cidofovir, CMX-001, maribavir. Acyclovir has no known therapeutic efficacy against CMV and is allowable as standard of care to prevent Herpes simplex virus (HSV)
- RECIPIENT: Prophylactic therapy with CMV immunoglobulin or prophylactic antiviral CMV treatment (Letermovir is permitted). EXCEPT for low risk patients [8/8 high resolution HLA donor allele matching HCT])
- RECIPIENT: Other investigational product - concurrent enrollment in other clinical trials using any investigational new drug (IND) drugs with unknown effects on CMV or with unknown toxicity profiles is prohibited
- RECIPIENT: Other medications that might interfere with the evaluation of the investigational product
- RECIPIENT: Diagnosis with autoimmune disease
- RECIPIENT: Pregnant women and women who are lactating. The risks of CMV-MVA-Triplex to pregnant women are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother. Breastfeeding should be discontinued if the mother is enrolled on this study
- RECIPIENT: Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., social/ psychological issues, etc
- RECIPIENT: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 지지 요법
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Donor (multi-peptide CMV-modified vaccinia Ankara vaccine)
Donors receive multi-peptide CMV-modified vaccinia Ankara vaccine injection between days -60 and -10 prior to granulocyte colony stimulating factor mobilization. |
Given via injection
다른 이름들:
|
|
실험적: Receipient (multi-peptide CMV-modified vaccinia Ankara vaccine)
Participants undergo hematopoietic cell transplantation on day 0 and receive multi-peptide CMV-modified Vaccinia Ankara vaccine injection on days 28 and 56. |
Given via injection
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Delayed Engraftment
기간: Up to 1 year from stem cell infusion.
|
Time to neutrophil engraftment was defined as days from stem cell infusion to the first of three consecutive days of absolute neutrophil count ≥0.5 x 109/L. Delayed engraftment was defined as ≥20 days to neutrophil recovery. |
Up to 1 year from stem cell infusion.
|
|
Severe (Grade III-IV) Acute Graft Versus Host Disease
기간: Up to 6 months from stem cell infusion
|
Acute graft versus host disease (aGvHD) happens within days or as late as 6 months after allogeneic transplants. The three main tissues that acute GVHD affects are the skin, liver, and gastrointestinal tract. |
Up to 6 months from stem cell infusion
|
|
Number of Recipients With Grade 3-4 Adverse Events
기간: Up to 1 year from stem cell infusion.
|
Toxicities were assessed in recipients by Common Terminology Criteria for Adverse Events version 4.0. |
Up to 1 year from stem cell infusion.
|
|
Number of Donors With Grade 2-3 Adverse Events
기간: Up to 6 months after G-CSF mobilization
|
Toxicities were assessed in recipients by Common Terminology Criteria for Adverse Events version 4.0. |
Up to 6 months after G-CSF mobilization
|
|
100-Day Non-Relapse Mortality (NRM)
기간: From stem cell infusion up to 100 days post-HSCT (hematopoietic stem cell transplantation).
|
NRM was defined as death without recurrent or progressive disease after allogeneic transplant. Probabilities of NRM were estimated with the use of cumulative incidence curves, with relapse viewed as a competing risk. |
From stem cell infusion up to 100 days post-HSCT (hematopoietic stem cell transplantation).
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Ryotaro Nakamura, MD, City of Hope Medical Center
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 18007
- 18007 (기타 식별자: City of Hope Medical Center)
- NCI-2018-01115 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .